New Data From NeffyTM (ARS-1) Studies Profiled by AAAAI

According to data ARS Pharmaceuticals originally planned to present at the 2020 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) before its cancellation due to the situation with coronavirus disease 2019 (COVID-19), Neffy 1 mg has the potential to be the first intranasal epinephrine spray product...

ARS Pharmaceuticals to Present New Data from Neffy™ (ARS-1) Studies at AAAAI 2020 Annual Meeting

First presentation of findings from EPI03, EPI04 and EPI07 studies that examine the pharmacokinetics and pharmacodynamics of single and repeat administration of epinephrine after intranasal, intramuscular and subcutaneous administration Additional analyses measure the effects of active seasonal allergic rhinitis symptoms on the absorption of intranasal epinephrine administered as Neffy™, and...

ARS Pharmaceuticals Announces the Appointment of Two New Board Members

Expansion of Board of Directors Adds Commercialization and Financial Expertise,  Further Augments Clinical and Scientific Acumen of Medical and Scientific Advisory Board  SAN DIEGO – June 18, 2019 – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions...

ARS Pharmaceuticals Announces Results from EPI-04 Clinical Study of ARS-1 Intranasal Epinephrine Spray in Allergy Patients with Allergic Rhinitis

Results demonstrate rapid epinephrine absorption with an overall pharmacokinetic profile comparable to epinephrine injection in allergy-induced patients SAN DIEGO--(BUSINESS WIRE)--ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, today announced results from its EPI-04...